FDA clears MindMaze GO neurorehabilitation platform, easing access to continued outpatient therapy

By SharpBrains | June 13, 2018

___ Mind­Maze Con­sol­i­dates First-ever FDA Approval for Inpa­tient and Out­pa­tient Neu­rore­ha­bil­i­ta­tion Ther­a­py (press release): “Mind­Maze, a leader in brain­tech, has today announced that it has obtained FDA clear­ance to launch its portable neu­rore­ha­bil­i­ta­tion prod­uct, Mind­Mo­tion™ GO, in the Unit­ed States. Togeth­er with Mind­Mo­tion PRO (which received FDA clear­ance in 2017), Mind­Mo­tion GO is the next…

Read More

Exploring the latest in cognitive rehabilitation and brain health

By SharpBrains | January 4, 2017

Expo Day: Mind­Maze, Sharp­Brains, Wat­son Cen­tre for Brain Health from Sharp­Brains Dur­ing Expo Day select­ed Sum­mit Part­ners and Spon­sors show­cased their lat­est ini­tia­tives and solu­tions. Dr. Daniel Perez-Mar­­cos, Senior Sci­en­tist at Mind­Maze, pre­sent­ed the Mind­Mo­tion platform–a series of med­i­cal-grade vir­tu­al real­i­ty solu­tions for neu­rore­ha­bil­i­ta­tion. Alvaro Fer­nan­dez. Sharp­Brains‘ CEO & Edi­­tor-in-Chief dis­cussed The State of Brain…

Read More